Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome
Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome
About this item
Full title
Author / Creator
Kuang, Fei Li , Legrand, Fanny , Makiya, Michelle , Ware, JeanAnne , Wetzler, Lauren , Brown, Thomas , Magee, Tamika , Piligian, Brent , Yoon, Pryscilla , Ellis, Jamie H , Sun, Xiaoping , Panch, Sandhya R , Powers, Astin , Alao, Hawwa , Kumar, Sheila , Quezado, Martha , Yan, Li , Lee, Nancy , Kolbeck, Roland , Newbold, Paul , Goldman, Mitchell , Fay, Michael P , Khoury, Paneez , Maric, Irina and Klion, Amy D
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Benralizumab, an interleukin-5 receptor blocker, significantly reduced absolute eosinophil counts and relieved symptoms in a small group of patients with hypereosinophilic syndrome. Adverse events were similar in the benralizumab group and the placebo group.
Alternative Titles
Full title
Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome
Authors, Artists and Contributors
Author / Creator
Legrand, Fanny
Makiya, Michelle
Ware, JeanAnne
Wetzler, Lauren
Brown, Thomas
Magee, Tamika
Piligian, Brent
Yoon, Pryscilla
Ellis, Jamie H
Sun, Xiaoping
Panch, Sandhya R
Powers, Astin
Alao, Hawwa
Kumar, Sheila
Quezado, Martha
Yan, Li
Lee, Nancy
Kolbeck, Roland
Newbold, Paul
Goldman, Mitchell
Fay, Michael P
Khoury, Paneez
Maric, Irina
Klion, Amy D
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6557265
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6557265
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1812185
